Abstract. Background Every day worldwide women are diagnosed with malignant breast cancer with aggressiveness related to the age of patients (1). Today life expectancy of breast cancer patients is very high, but is often affected by the long-term side effects of oncological treatments. Breast tumors are often hormone-sensitive, and among the therapeutic options, endocrine therapy is currently used and includes tamoxifen, aromatase inhibitors and LHRH analogues (2). The decreased level of circulating estrogens due to the abovementioned therapy, in addition to the menopause condition, are responsible for atrophic vaginitis and urinary disorders. The latter are characterized by symptoms ranging from moderate to severe. Today an increasing interest on patient's quality of life is taken by physicians, especially medical oncologists, by focusing both on the most effective treatment and on minimizing the treatments' side-effects, including those of uro-gynecological nature. Estrogen deficiency due to the oncological treatments, chemotherapy and endocrine therapy, induces the uro-genital syndrome as much as is the case of postmenopausal women. The genitourinary postmenopausal syndrome is defined as a set of signs and symptoms associated with the reduction of circulating estrogens that determines changes in the vagina, vulva, bladder and urethra and that severely impairs women's quality of life.Women with breast cancer in endocrine adjuvant treatment, if not yet in physiological menopause, experience a temporary estrogen deficiency induced by the treatment itself. Similarly, to the aggressiveness of the tumor, the symptoms and signs of uro-genital syndrome may be more debilitating the younger the women are (3). The uro-genital symptoms of estrogen deficiency are vaginal dryness, burning and irritation, sexual symptoms such as the lack of lubrication and dyspareunia and urinary symptoms such as urgency, frequency, incontinence and recurrent urinary tract infections. The genitourinary syndrome, that is accompanied by atrophy of the urological mucosa, is characterized by recurrent bacterial cystitis and post-coital cystitis mostly incurred from gram-negative bacteria (4). The most bothersome urinary symptoms associated with bacteriuria are urgency, increasing voiding frequency, pain and urinary incontinence. Bacteria that colonize the bladder are mostly gram negative and of intestinal origin. They have a specific pathogenesis activity underlying the chronicity of the phenomenon which hardly 931